NIP
ELVN icon

Nicholas Investment Partners’s Enliven Therapeutics ELVN Stock Holding History

Nicholas Investment Partners’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.16M Buy
+182,728
New +$5.06M 0.52% 72
2025
Q1 		– Sell
-157,635
Closed -$3.55M – 208
2024
Q4 		$3.55M Sell
157,635
-16,110
-9% -$418K 0.31% 116
2024
Q3 		$4.44M Buy
173,745
+117,673
+210% +$2.73M 0.41% 93
2024
Q2 		$1.31M Buy
+56,072
New +$1.18M 0.14% 158

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nicholas Investment Partners's ELVN Position: Q1 2026 in Review

Nicholas Investment Partners opened a new position in Enliven Therapeutics (ELVN) in Q1 2026: 182,728 shares worth $7.16M. The stake represents 0.52% of the portfolio and ranks #72 among its holdings. This is a return to the name: Nicholas Investment Partners previously reported a position in ELVN as recently as Q4 2024.

Nicholas Investment Partners first reported a position in ELVN in Q2 2024 and has held it in 4 quarters since. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • Nicholas Investment Partners held 182,728 shares of Enliven Therapeutics worth $7.16M as of Q1 2026.
  • Enliven Therapeutics was a new Nicholas Investment Partners position in Q1 2026.
  • Enliven Therapeutics made up 0.52% of Nicholas Investment Partners's portfolio in Q1 2026, its #72 holding.
  • Nicholas Investment Partners first reported a position in Enliven Therapeutics in Q2 2024 and has held it in 4 quarters since.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on Nicholas Investment Partners's 13F filing for Q1 2026, filed 15 May 2026.